Learn about who we are, what we believe
and the people who lead us
Discover our unique scientific approach
for diseases with high unmet need.
The first and only FDA-approved
treatment for Demodex blepharitis
Explore the possibilities of our robust pipeline
to address significant unmet patient needs
Find additional corporate
and stock information.
TP-04: An investigational therapeutic for the potential treatment of papulopustular rosacea (PPR)1
Real patient with PPR.
TP-04 is a topical, aqueous gel formulation of lotilaner in development for the potential treatment of papulopustular rosacea (PPR).1
According to the National Rosacea Society, approximately 16 million people in the US are affected by rosacea,2 a chronic skin disease characterized by facial redness, inflammatory lesions, burning and stinging. PPR, estimated to occur in 18% to 28% of patients with rosacea, can result in redness, swelling and/or pus-filled bumps.3-6
GABA=gamma-aminobutyric acid.
1. [Tarsus Initiates Phase 2 Trial Evaluating TP-04, a Novel, Aqueous Gel Formulation of Lotilaner, for the Treatment of Papulopustular Rosacea.] Press release. March 13, 2023. 2. Rosacea now estimated to affect at least 16 million Americans. Rosacea Review. Accessed September 30, 2024. https://www.rosacea.org/rosacea-review/2010/winter/rosacea-now-estimated-to-affect-at-least-16-million-americans 3. Abram K, Silm H, Oona M. Prevalence of rosacea in an Estonian working population using standard classification. Acta Derm Venereol. 2010;90(3):269-273. 4. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Brit J Dermatol. 2018;179(2):282-289. 5. Kyriakis KP, Palamaras I, Terzoudi S, Emmanuelides S, Michailides C, Pagana G. Epidemiologic aspects of rosacea. J Am Acad Dermatol. 2005;53(5):918-919. 6. Tan J, Schofer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M; RISE study group. Prevalence of rosacea in the general population of Germany and Russia – the RISE study. J Eur Acad Dermatol Venereol 2016;30:428-434. 7. Forton FM. The pathogenic role of Demodex mites in rosacea: a potential therapeutic target already in erythematotelangiectatic rosacea? Dermatol Ther (Heidelb). 2020;10(6):1229-1253. 8. Rosacea pipeline update: Tarsus starts phase 2A trial of TP-04 in PPR. Practical Dermatology. Published March 14, 2023. Accessed September 30, 2024. https://practicaldermatology.com/news/rosacea-pipeline-update-tarsus-starts-phase-2a-trial-of-tp-04-in-ppr
Our Terms of Use and Privacy Policy have changed.
By clicking accept, you agree that you have read and will abide by these new terms.
